To support its international expansion and strengthen technology differentiation, ImmunAdd, Inc. today announced that its proprietary next-generation fully synthetic vaccine adjuvant platform has been formally named ImmSygma™ (ImmunAdd Synthetic GlycoMolecule Adjuvants). The Sygma in the platform name echoes the Greek letter Sigma (Σ), carrying a dual meaning of summation and precision—reflecting both the synergy of […]
ImmunAdd has completed the manufacturing and pharmacology/toxicology studies required for the preclinical trials of its next-generation saponin adjuvant. Offering sustainable supply and lower toxicity, the adjuvant holds significant application value in the vaccine field. The company has been steadily expanding its business development (BD) team and is actively attending major international conferences to engage global […]
ImmunAdd today announced an update on the progress of its patent portfolio. Effective this year, the company has adopted a new disclosure policy under which it no longer announces the grant or filing status of individual patents on a case-by-case basis, and instead provides periodic, consolidated updates on the overall progress of its portfolio. As […]
Taipei, July 17, 2025 ––ImmunAdd Inc. is pleased to announce its participation in BIO Asia–Taiwan 2025, taking place from July 24 to July 27 at TaiNEX 2 (Taipei Nangang Exhibition Center Hall 2). During the exhibition, ImmunAdd will present key achievements from its next-generation vaccine adjuvant platform and engage with domestic and international partners across […]
TAIPEI, Taiwan May 15, 2025 – Japan Patent Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan May 12, 2025 – U.S. Patent and Trademark Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Mar. 5, 2025 – Korean Intellectual Property Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Oct. 23, 2024 – The Israel Patent Office has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Oct. 23, 2024 – China National Intellectual Property Administration has granted ImmunAdd the patent on saponin conjugate and vaccine or pharmaceutical composition comprising the same. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan Jul. 10, 2024 – ImmunAdd won the Startup of the Year at the 2024 Taiwan BIO Awards and the Awards ceremony will be held on July 25th. ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. ImmunAdd was founded in 2022 but has put efforts into […]
- 1
- 2